Literature DB >> 11717182

Population distribution of human flavin-containing monooxygenase form 3: gene polymorphisms.

J R Cashman1, J Zhang, J Leushner, A Braun.   

Abstract

The N-oxygenation of amines by the human flavin-containing monooxygenase (form 3) (FMO3) represents an important means for the conversion of lipophilic nucleophilic heteroatom-containing compounds into more polar and readily excreted products. Certain mutations of the human FMO3 gene have been linked to abnormal drug or chemical metabolism. For example, abnormal N-oxygenation of trimethylamine has been shown to segregate with mutations of human FMO3. To date, however, it is not known whether there is a pharmacogenetic basis for abnormal drug metabolism by human FMO3. The objective of this study was to estimate the allele and genotype frequencies at three variable DNA sites in the FMO3 gene in male and female blood bank donors representative of non-Hispanic Caucasians, non-Hispanic African Americans, Hispanics, and Asians sampled from the United States. The common polymorphisms at variable sites 158, 257, and 308 were experimentally determined using a high-throughput chip-based genotype variation detection method combining MassEXTEND and matrix-assisted laser desorption ionization time-of-flight mass spectrometry. We also compared the genetic variation of nonhuman primate FMO3 with the human FMO3 gene. Exon sequence analysis of the monkey FMO3 gene sequence showed that it was similar to the human gene sequence but differed from the human consensus sequence at 31 fixed positions. Compared with that of human, the chimpanzee exon sequence had one polymorphism that induced an amino acid change. The evolutionary history of the FMO3 gene was inferred from the pattern of haplotype relationships across different populations and species. Statistically significant heterogeneity in the relative frequencies of single and multiple site alleles, haplotypes, and genotypes of the human FMO3 among ethnic subdivisions suggests that population differences in the susceptibility of humans to abnormal metabolism or adverse drug reactions for chemicals metabolized by human FMO3 could exist.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11717182

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  7 in total

Review 1.  Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism.

Authors:  Sharon K Krueger; David E Williams
Journal:  Pharmacol Ther       Date:  2005-06       Impact factor: 12.310

2.  A common FMO3 polymorphism may amplify the effect of nicotine exposure in sudden infant death syndrome (SIDS).

Authors:  Micaela Poetsch; Marco Czerwinski; Lisa Wingenfeld; Mechtild Vennemann; Thomas Bajanowski
Journal:  Int J Legal Med       Date:  2010-03-03       Impact factor: 2.686

3.  Novel variants of the human flavin-containing monooxygenase 3 (FMO3) gene associated with trimethylaminuria.

Authors:  Meike S Motika; Jun Zhang; Xueying Zheng; Kiersten Riedler; John R Cashman
Journal:  Mol Genet Metab       Date:  2009-02-27       Impact factor: 4.797

Review 4.  Genetic polymorphisms of human flavin-containing monooxygenase 3: implications for drug metabolism and clinical perspectives.

Authors:  Irfan M Hisamuddin; Vincent W Yang
Journal:  Pharmacogenomics       Date:  2007-06       Impact factor: 2.533

5.  Effect of Choline Forms and Gut Microbiota Composition on Trimethylamine-N-Oxide Response in Healthy Men.

Authors:  Clara E Cho; Niklas D J Aardema; Madison L Bunnell; Deanna P Larson; Sheryl S Aguilar; Janet R Bergeson; Olga V Malysheva; Marie A Caudill; Michael Lefevre
Journal:  Nutrients       Date:  2020-07-25       Impact factor: 5.717

6.  Effects of Genetic Variants in the Nicotine Metabolism Pathway on Smoking Cessation.

Authors:  Huijie Li; Qiang Wang; Suyun Li; Chongqi Jia
Journal:  Genet Res (Camb)       Date:  2022-09-28       Impact factor: 1.375

7.  Effect of human flavin-containing monooxygenase 3 polymorphism on the metabolism of aurora kinase inhibitors.

Authors:  Gianluca Catucci; Andrea Occhipinti; Massimo Maffei; Gianfranco Gilardi; Sheila J Sadeghi
Journal:  Int J Mol Sci       Date:  2013-01-28       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.